Menu Search
Equities

Ono Pharmaceutical Co Ltd

4528:TYO

Ono Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)1,755.00
  • Today's Change8.50 / 0.49%
  • Shares traded852.50k
  • 1 Year change-37.34%
  • Beta0.6503
Data delayed at least 20 minutes, as of Nov 22 2024 04:23 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy0
Outperform2
Hold5
Sell5
Strong Sell1

Share price forecast in JPY

The 11 analysts offering 12 month price targets for Ono Pharmaceutical Co Ltd have a median target of 1,900.00, with a high estimate of 4,370.00 and a low estimate of 1,700.00. The median estimate represents a 8.79% increase from the last price of 1,746.50.
High150.2%4,370.00
Med8.8%1,900.00
Low-2.7%1,700.00

Dividends in JPY

In 2024, Ono Pharmaceutical Co Ltd reported a dividend of 80.00 JPY, which represents a 14.29% increase over last year. The 12 analysts covering the company expect dividends of 77.59 JPY for the upcoming fiscal year, a decrease of 3.01%.
Div growth (TTM)14.29%
More ▼

Earnings history & estimates in JPY

On Oct 30, 2024, Ono Pharmaceutical Co Ltd reported 2nd quarter 2025 earnings of 35.87 per share.
The next earnings announcement is expected on Jan 28, 2025.
Average growth rate-13.99%
Ono Pharmaceutical Co Ltd reported annual 2024 earnings of 266.61 per share on May 08, 2024.
Average growth rate+23.18%
More ▼

Revenue history & estimates in JPY

Ono Pharmaceutical Co., Ltd. had 2nd quarter 2025 revenues of 122.66m. This bettered the 119.24m consensus of the 4 analysts covering the company. This was 2.21% above the prior year's 2nd quarter results.
Average growth rate-2.72%
Ono Pharmaceutical Co., Ltd. had revenues for the full year 2024 of 502.67m. This was 70.37% above the prior year's results.
Average growth rate+18.66%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.